Providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities, SMi presents the 20th annual Superbugs & Superdrugs conference which will return to Central London on 19th and 20th March 2018. The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders, drug discovery specialists and government bodies such as MHRA and DNDi.

1. www.superbugssuperdrugs.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
PLUS ONE INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 21st March 2018, Copthorne Tara Hotel, Kensington, London, UK
@SMIPHARM
#smibugs
SMi present their 20th Annual Conference on…
Superbugs &
Superdrugs
Tackling the scientific, regulatory and economic
challenges to combat anti-microbial resistance
COPTHORNE TARA HOTEL, KENSINGTON, LONDON, UK
The Use of Animal Models in Pre-Clinical Drug Development
08.30 – 12.30
Workshop Leaders:
William Weiss, Director, Pre-Clinical Services, UNT System College of Pharmacy
Mark Pulse, Assistant Director, Pre-Clinical Services, UNT System College of Pharmacy
BOOK BY 30TH NOVEMBER AND SAVE £400
BOOK BY 15TH DECEMBER AND SAVE £200
BOOK BY 31ST JANUARY AND SAVE £100
CONFERENCE: 19TH - 20TH
WORKSHOP: 21ST
MAR 2018
Featuring
exclusive
MHRA
keynote
address
NEW FOR 2018:
• Analyse the current status of antimicrobial resistance with
industry led insight into current strategies to tackle AMR
• Hear exclusive case studies from a selection of
pharmaceutical companies on clinical progress
• Learn about regulatory pathways for the registration of new
antimicrobial agents
• Evaluate the latest incentives and funding solutions to spur
drug discovery
• Evaluate the latest novel alternatives to antibiotics currently in
development
CHAIRS FOR 2018:
Richard Bax, Lloyd Czaokewski,
Senior Partner, Director,
TranScrip Partners Chemical Biology Ventures
FEATURED SPEAKERS:
Cara Cassino, Chief Medical Officer and Executive Vice
President of Research and Development, Contrafect
Kathy Talkington, Project Director, Antimicrobial
Resistance, The Pew Charitable Trusts
Jean-Pierre Paccaud, Director of Business Development
and Development Strategy, GARDP, DNDi
John George, Founder/CSO,
Oppilotech
Domingo Gargallo-Viola, Chief Scientific Officer,
ABAC Therapeutics
William Weiss, Director of Pre-Clinical Services,
University of North Texas Health Science Center
Larry Sutton, Scientific Founder,
Gladius Pharmaceuticals
ATTENDEE TESTIMONIALS FROM 2017
“Very good & informative meeting”
University Medical Center Utrecht
“Good first experience. Good
to see some presentations on
novel approaches”
Immuno Research Inc

2. *Subject to final confirmation
Superbugs & Superdrugs
Day One | Monday 19th March 2018 www.superbugssuperdrugs.com
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Richard Bax, Senior Partner, Transcrip Partners
FUNDING & INCENTIVES
09.15 OPENING ADDRESS
GARDP: an alternative model to antibiotic drug development
• GARDP is a not-for-profit R&D organisation developing new
treatments to tackle durg-resistant bacterial infections , and
aiming at delivering them in a responsible, sustainable and
accessible manner
• Public-private partnerships contributions to fight AMR:
collaboration and complementarity
• Experimenting alternative business models to deliver innovation
• Current programs and deals will be presented
Dr Jean-Pierre Paccaud, Director of Business Development
and Development Strategy, GARDP, DNDi
09.55 KEYNOTE ADDRESS
Tackling the current lack of incentives for people working in
antimicrobial resistance research and development
• Analysis of the economic issues which affect the research
and development of new antibiotics in the private sector?
• Using ‘risk-sharing’ arrangements between health care payers
and pharmaceutical companies to drive new development
• Which push incentives are the most beneficial and could
similar results be achieved using relevant pull incentives?
• How to ensure that financial incentives for the private sector,
does not prevent drug accessibility to developing countries?
Adrian Towse, Director, Office of Health Economics*
10.35 Morning Coffee
STRATEGIES TO RESURRECT PATHOGEN SENSITIVITY TO ANTIBIOTICS
11.05 Bacterial cybergenetics to resurrect sensitivity to antibiotics in
anti-microbial resistant (AMR) pathogens
• “Nemesis Symbiotics” use programmable RNA-guided DNA
endonuclease gene editing technology to target antibiotic
resistance genes
• A single Symbiotic inactivates members of multiple families
of resistance genes –so resurrecting sensitivity to antibiotics
• Pre-clinical studies show that Transmids, our novel vectors,
deliver Symbiotics to bacteria by phage-coat infection and
subsequently spread by bacterial conjugation
• Symbiotics are biological companion therapeutics to be
used together with well-established antibiotics for both
therapeutic treatment of infection as well as prophylactic
treatment preventing the spread of AMR
Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience
11.45 Using immune modulation alongside antibiotics to counter
multidrug-resistant bacteria
• The antibiotic field can arguably learn from oncology where
immune modulation used alongside chemotherapy has
transformed treatment prospects
• Similarly, to beat resistant bacteria, we need to counter the
way they usurp our immune defenses to evade antibiotics
• Summarising novel ideas on using immune modulation
alongside antibiotics to beat resistant species
• Suggesting that adding a third component could reduce
death rates from sepsis which remain very high even with
use of modern antibiotics
David Brown, Managing Director and Founder,
Alchemy Biomedical Consulting
12.25 Networking Lunch
STRATEGIES TO ASSIST THE DEVELOPMENT OF NEW THERAPEUTICS & DRUGS
KEYNOTE ADDRESS
13.35 SPARKing New Antibiotic Discovery
– the Shared Platform for Antibiotic Research and Knowledge
• The Shared Platform for Antibiotic Research and Knowledge
is a groundbreaking and dynamic information-sharing platform
• Bringing together curated antibiotic discovery data and
cutting-edge analytics to help scientists tackle the scientific
barriers blocking antibiotic discovery
• While the global threat of antibiotic resistance continues
to rise, nearly every antibiotic in use today is based on a
discovery from more than 30 years ago
• SPARK will focus on the unique challenges of finding
and designing antibiotics that can defeat drug-resistant
Gram-negative bacteria, which are among the
hardest-to-treat superbugs
Kathy Talkington, Project Director, Antimicrobial Resistance,
The Pew Charitable Trusts
14.15 Use of the PasNas platform to enable high quality
antibacterial hit finding
• The infectious diseases drug discovery is enormously
inefficient. We can not repeat things over and over again.
What can we do to change this trend?
• Disruptive Innovation to control risk factors, improve
efficiency and ensure delivery
• New paradigms in infectious diseases, from magic bullet
to precision antibacterial agents
Domingo Gargallo-Viola, Chief Scientific Officer,
ABAC Therapeutics
14.55 Afternoon Tea
15.25 Building a detailed computational network model of cell
envelope biogenesis: a systems biology approach to
developing antibacterial drugs (potentiators)
• Model incorporates the synthesis of key components
including LPS, phospholids and peptidoglycan
• The model is used to guide the identification of potentiator
targets– agents that can enhance the activities of existing
antibiotics
• Potentiator programmes derived from model
John George, Founder/CSO, Oppilotech
16.05 Teaching old cephalosporin dogs new mechanistic tricks
against MDR Gram-negative bacteria
• Cephalosporin synthetic scaffolding for new mechanisms
• In vitro activity versus WHO critical priority pathogens
• Comparison to new combination ß-lactams
• In vivo performance
Larry Sutton, Scientific Founder, Gladius Pharmaceuticals
16.45 Novel virulence factors of Acinetobacter baumannii as targets
for antibacterial development
• Over the past 3-4 years, my team has exploited a transposon
mutant library to identify targets required for A. baumannii
virulence in animal models of infection
• Some of these genes/proteins are novel targets on the
surface of the bacterium that we are currently developing
human monoclonal antibodies against
• We have also identified some targets within the bacterium
that could be drug-able
• As we learn and test more, we believe the true strength of
our research is not a single attack against the bacteria, but
rather a combination of multiple drugs/antibodies against
different targets to render the bacteria avirulent and
cleared by the immune system
Daniel Zurawski, Head, Antibacterial Discovery and
Development, Walter Reed Army Institute of Research
(WRAIR)/Bacterial Diseases Branch
17.25 Chairman’s Closing Remarks and Close of Day One
Welcome Letter from our 2018 Chairs
Dear Colleagues,
It is with great pleasure that we welcome you to participate in the
20th Annual Superbugs & Superdrugs Conference taking place on
19th - 20th March 2018, Central London, UK.
We are delighted to chair this annual industry meeting in 2018 again, which
will gather a high level of international experts and project decision makers
to review the successes of 2017 and look to the future of AMR.
This year’s conference has an exciting mix of traditional and alternative
approaches, industry and academia, funders and regulators.
Yours Sincerely,
Richard Bax,
Senior Partner,
TranScrip Partners
Lloyd Czaplewski,
Director,
Chemical Biology
Ventures
Register online at www.superbugssuperdrugs.com
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion
specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Official Media Partners

3. Superbugs & Superdrugs
www.superbugssuperdrugs.com Day Two | Tuesday 20th March 2018
Supported by
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
MARKETING OPPORTUNITIES
Want to know how you can get involved? Interested in promoting your services to this market?
Contact – Teri Arri SMi Marketing on +44 (0) 20 7827 6162 or email: tarri@smi-online.co.uk
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Lloyd Czaplewski, Director, Chemical Biology Ventures
OPENING ADDRESS
09.10 Highlights from the Traditional and Alternative Antibacterial
Pipeline
• What new therapies can we anticipate?
• Research challenges
• Are we asking the right questions?
Lloyd Czaplewski, Director, Chemical Biology Ventures
REGULATIONS & CONSIDERATIONS
KEYNOTE ADDRESS
09.50 Regulatory considerations for the registration of new
antibacterial agents
• Ensuring that candidate antibacterial agents with potential
to address an unmet need are evaluated in line with
regulatory guidance
• Options for clinical development programmes
• Importance of the pharmacokinetic-pharmacodynamic
relationship
• Update on recent guidance and planned revisions to EMA
guidance
Mair Powell, Medical Assessor, MHRA
10.30 Morning Coffee
RESEARCH ADVANCES IN ANTIBIOTIC DEVELOPMENT
KEYNOTE ADDRESS
11.00 Iclaprim: a well differentiated, targeted, potent and rapidly
bactericidal antibiotic against multidrug resistant bacteria
• Exploring a novel mechanism of action different from any
other antibiotic currently in development
• Positive clinical outcomes among patients with ABSSSI
and HAP/VAP through optimizing iclaprim’s dose and the
concentration at sites of infection
• Looking into safety data and what lies ahead to achieve
FDA and EMA approval
David Huang, Chief Medical Officer, Motif BioSciences, Inc
11.40 Opening up new opportunities for the treatment of infectious
diseases using nanoformulations
• Nanoformulations formulate drugs into nanoparticles
and can greatly enhance their pharmacokinetic and
pharmacodynamics properties
• Exploring the potential of novel drug nanoformulations to
create new treatments for infections
• Presentation of research and discussion of the potential of
nanoformulations more broadly in infectious disease
David Cook, Chief Scientific Officer,
Blueberry Therapeutics Ltd.
12.20 Networking Lunch
13.20 Challenges in Antimicrobial Evaluation of Novel Therapies
using Animal Models
• Where to start / What model to use
• Dose / Regimen – How to choose
• Test articles with no intrinsic activity
• How to evaluate combination therapy
• What does the data tell us?
William Weiss, Director of Pre-Clinical Services,
University of North Texas Health Science Center
NOVEL CANDIDATES AND ALTERNATIVES TO ANTIBIOTICS
KEYNOTE ADDRESS
14.00 Lysins: Alternative Antimicrobials to Improve Clinical
Outcomes Serious Bacterial Infections - CF-301 - A Case Study
• CF-301 demonstrates the hallmark features of lysins,
including: rapid, targeted bacteriolysis, potent synergy with
conventional antibiotics, activity against antibiotic-resistant
strains, low propensity for resistance and remarkable biofilm
eradication, which make lysins attractive therapeutic
candidates for serious bacterial infections.
• In vivo studies with CF-301 signal the therapeutic potential
of lysins boost the efficacy of conventional antibiotics and
combat antimicrobial resistance
• The ongoing CF-301 clinical development program will help
define the place in therapy for ability of lysin therapeutics in
the treatment of serious, invasive,
biofilm-dependent bacterial infections is being evaluated in
clinical development
Cara Cassino, Executive Vice President of Research and
Development and Chief Medical Officer,
Contrafect Corporation
14.40 Afternoon Tea
15.10 C. auris – a difficult to treat, emerging pathogen
• Brief history of C. auris
• How C. auris differs from other candida species
• Experimental models of C. auris
• New potential treatments
Stephen A. Barat, Head of Pre-Clinical Research and Early
Clinical Development, Scynexis
15.50 Amelioration of multi drug resistant infection by antibody
modulation
• Some individuals overproduce antibody that recognises
surface structures on bacteria
• Such antibody interferes with serum killing of the bacterium
• Removal of these antibodies by apharesis restores serum
killing
• Restoration of serum killing is associated with clinical
improvement
Ian R. Henderson, Professor of Microbial Biology,
Director, Institute of Microbiology and Infection,
University of Birmingham
16.30 Chairman’s Closing Remarks and Close of Day Two

4. The Use of Animal Models in Pre-Clinical
Drug Development
Workshop Leaders:
William Weiss, Director, Pre-Clinical Services,
UNT System College of Pharmacy
Mark Pulse, Assistant Director, Pre-Clinical Services,
UNT System College of Pharmacy
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 21st March 2018
08.30 – 12.30
Copthorne Tara Hotel, Kensington, London, UK
Overview of Workshop:
The workshop will provide an overview of the use of animal
models in preclinical drug development. We will focus on the
transition from in vitro activity to in vivo efficacy, the choice of
the right animal model for proof of concept studies, provide
examples of relevant animal models with supportive data and
interpretation of results as they relate to the clinical condition.
Reason to attend:
• To gain an understanding of what animal models can and
cannot provide
• To learn how animal model endpoints relate to clinical
endpoints
• In depth discussion of how models are performed
• Regulations and constraints in the performance of these
models
Programme:
08.30 Registration & Coffee
09.00 Preclinical Animal Models
• Opening remarks and introduction
• History of animal testing
• The general use of animals in research
• Are animal models predictive?
09.30 Experimental Design and Methodology
• How to design the most relevant study for your needs
• Factors that need to be considered – Before, during
and after
• Realistic objectives - What you can and can’t do
• Advantages and Disadvantages
10.30 Morning Coffee
11.00 Animal Models – Examples
• Clinical relevance of current models
• Acute and chronic infection models – From
bacteremia to pneumonia
• GI related infections
• Implanted device infections
• Antifungal testing
• Pharmacokinetics / Pharmacodynamics
12.00 Ethical Use of Animals in Research
• Oversight of animal use in biomedical research
• IACUC – Friend or Foe?
• Governing agencies and regulations for animal
models
• Replace / Refine / Reduce
12.30 Final discussion and close of Workshop
About the Workshop Leaders:
William Weiss Before leading the PreClinical Services
group, Bill was Director of Drug Evaluation at
Cumbre Pharmaceuticals Inc. and a Group Leader
in Infectious Disease Discovery Research at Wyeth
Research (Pfizer), Lederle Laboratories and Schering-Plough
(Merck). His current responsibilities included leading in vitro
and in vivo evaluation of novel test articles from medicinal
synthetic and natural products chemistry. He has worked on
numerous antibacterial programs including the development
of Suprax, Zosyn and Tygacil. His expertise encompasses the
development of animal research models, evaluation of new
and novel therapeutic agents as well as pharmacokinetic /
pharmacodynamic analysis.
Mark Pulse Mark holds a Masters of Science degree
in molecular microbiology and immunology and
his early research at the University of North Texas
Health Science Center primarily focused on bacterial
pathogenesis and pre-clinical drug evaluation within in vivo
models. For the last 12 years he has been directly involved
in the development of multiple in vivo models that have
included GI- and respiratory-associated infectious diseases,
device-associated (biofilm) infections and pharmacokinetic
studies within multiple animal species. He also has experience
with survival surgery in multiple animal models, including USDA
species.
About the organisation:
The Pre-Clinical Services group at the University of North Texas
Health Science Center conducts studies utilizing established
models of both acute and chronic bacterial infections in
several different animal species. UNTHSC Pre-clinical Services
together has over 33 years of pharmaceutical and specialized
biotech experience in the performance of therapeutic
efficacy models and drug discovery / development. The group
uses this experience to guide the drug discovery process,
through protocol design, implementation and analysis for
compound lead selection.

5. SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and
branding packages, uniquely tailored to complement
your company’s marketing strategy. Prime networking
opportunities exist to entertain, enhance and expand
your client base within the context of an independent
discussion specific to your industry. Should you wish to
join the increasing number of companies benefiting
from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or
email: amalick@smi-online.co.uk
NOVEMBER 2017
Superbugs &
Superdrugs USA
13th - 14th November 2017
New Jersey, USA
Pharmaceutical
Microbiology East Coast
13th - 14th November 2017
New Jersey, USA
Biosimilars North America
15th - 16th November 2017
New Jersey, USA
Lyophilization USA
16th - 17th November 2017
New Jersey, USA
Ophthalmic Drugs
28th - 29th November 2017
London, UK
DECEMBER 2017
Cold Chain Distribution
13th - 14th December 2017
London, UK
JANUARY 2018
Pre-Filled Syringes Europe
17th - 18th January 2018
London, UK
Pharmaceutical
Microbiology
22nd - 23rd January 2018
London, UK
Social Media in the
Pharmaceutical Industry
22nd - 23rd January 2018
London, UK
FEBRUARY 2018
Parallel Trade
6th - 7th February 2018
London, UK
3D Cell Culture
21st - 22nd February 2018
London, UK
RNA Therapeutics
21st - 22nd February 2018
London, UK
MARCH 2018
Superbugs & Superdrugs
19th - 20th March 2018
London, UK
Paediatric Clinical Trials
19th - 20th March 2018
London, UK
Drug Discovery
21st - 22nd March 2018
London, UK
Controlled Release
Delivery
21st - 22nd March 2018
London, UK
APRIL 2018
Antibodies and Antibody
Drug Conjugates
9th - 10th April 2018
London, UK
Adaptive Designs
in Clinical Trials
9th - 10th April 2018
London, UK
Asthma & COPD
11th - 12th April 2018
London, UK
Pre-Filled Syringes
East Coast
11th - 12th April 2018
Boston, MA
MAY 2018
Pharmaceutical Freeze
Drying Technology
9th - 10th May 2018
London, UK
Injectable Drug Delivery
16th - 17th May 2018
London, UK
Pain Therapeutics
21st - 22nd May 2018
London, UK
Highly Potent Active
Pharmaceutical
Ingredients
21st - 22nd May 2018
London, UK
Drug Safety
23rd - 24th May 2018
London, UK
JUNE 2018
Pre-Filled Syringes
West Coast
4th - 5th June 2018
San Diego, CA
Pharmaceutical
Microbiology West Coast
7th - 8th June 2018
San Diego, CA
ADMET
11th - 12th June 2018
London, UK
Molecular Diagnostics
13th - 14th June 2018
London, UK
BioBanking
13th - 14th June 2018
London, UK
SMi Pharmaceutical
Forward Planner

6. Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-237 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
EARLY BIRD
DISCOUNT
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & Workshop £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ Workshop only £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-237
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE CopthorneTaraHotel,Kensington,ScarsdalePlaceKensingtonLondon,W85SR,UK
SUPERBUGS & SUPERDRUGS
Conference: Monday 19th & Tuesday 20th March 2018, Copthorne Tara Hotel, Kensington, London, UK
Workshop: Wednesday 21st March 2018, London, UK
4 WAYS TO REGISTER
www.superbugssuperdrugs.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd,
1 Westminster Bridge Road, London, SE1 7XW
□ Book by 30th November to receive £400 off the conference price
□ Book by 15th December to receive £200 off the conference price
□ Book by 31st January to receive £100 off the conference price